Elise Doaré1, François Robin2, Hélène Racapé3, Guillaume Le Mélédo1,4, Charles Orione5, Pascal Guggenbuhl2, Philippe Goupille4, Elisabeth Gervais6, Emmanuelle Dernis7, Béatrice Bouvard3, Thierry Marhadour1, Guillaume Coiffier2,8, Alain Saraux9,10. 1. Rheumatology Department, CHU, Centre de Référence Maladies Rares CERAINO, INSERM 1227, UBO, LabEx IGO, Brest CHU, Brest, France. 2. Rennes, Service de Rhumatologie, Institut NUMECAN (Nutrition Metabolisms and Cancer), Univ Rennes, INSERM, INRA, 35000, Rennes, France. 3. Rheumatology Department, CHU d'Angers, 49100, Angers, France. 4. Rheumatology Department, University Hospital of Tours; EA 7501, GICC, University of Tours, Tours, France. 5. Pneumology Department, CHU, Brest, France. 6. Rheumatology Department, CHRU de Poitiers, 86000, Poitiers, France. 7. Rheumatology Department, CH, Le Mans, France. 8. Rheumatology Unit, GHT Rance-Emeraude, CH, Dinan, France. 9. Rheumatology Department, CHU, Centre de Référence Maladies Rares CERAINO, INSERM 1227, UBO, LabEx IGO, Brest CHU, Brest, France. alain.saraux@chu-brest.fr. 10. Rheumatology Unit, Hôpital de la Cavale Blanche, BP 824, 29609, Brest Cedex, France. alain.saraux@chu-brest.fr.
Abstract
OBJECTIVES: The usual treatments for crystal-associated arthritis are sometimes contraindicated; thus, new therapies against interleukin-1beta (IL-1) have been developed. We evaluated the characteristics of patients who received biological treatment for crystal-associated arthritis. PATIENTS AND METHODS: We conducted a multicentric retrospective observational study in six rheumatology units in western France. Patients receiving a biological treatment for crystal-associated arthritis between 1 January 2010 and 31 December 2018 were included. Improvement was defined as at least a 50% decrease in the count of synovitis and C-reactive protein level. RESULTS: Forty-six patients were included: 31 (67.4%) were treated for gouty arthritis, and 15 (32.6%) for calcium pyrophosphate crystal deposition disease (CCPD). The first biotherapy used was anakinra for 14 patients (93.3%) with CCPD and 31 patients (100.0%) with gout. The first biotherapy course was more efficient in treating gout than in treating CCPD, with success in 28 patients (90.3%) and 5 patients (35.7%), respectively (p = 0.001). Six patients (42.9%) with CCPD stopped their first biotherapy course because of side effects. Among the patients with gout, urate-lowering therapy was more frequently used after (100%) than before the first biotherapy course (67.7%) (p = 0.002). CONCLUSION: Anakinra was prescribed for cases of refractory crystal-associated arthritis or cases with contraindications for usual treatments. The efficacy of anakinra in treating CCPD was not obvious. Patients with CCPD had more side effects. The biotherapy was introduced with a long-term objective, while anti-IL-1 therapies are approved for acute crises only.
OBJECTIVES: The usual treatments for crystal-associated arthritis are sometimes contraindicated; thus, new therapies against interleukin-1beta (IL-1) have been developed. We evaluated the characteristics of patients who received biological treatment for crystal-associated arthritis. PATIENTS AND METHODS: We conducted a multicentric retrospective observational study in six rheumatology units in western France. Patients receiving a biological treatment for crystal-associated arthritis between 1 January 2010 and 31 December 2018 were included. Improvement was defined as at least a 50% decrease in the count of synovitis and C-reactive protein level. RESULTS: Forty-six patients were included: 31 (67.4%) were treated for gouty arthritis, and 15 (32.6%) for calcium pyrophosphatecrystal deposition disease (CCPD). The first biotherapy used was anakinra for 14 patients (93.3%) with CCPD and 31 patients (100.0%) with gout. The first biotherapy course was more efficient in treating gout than in treating CCPD, with success in 28 patients (90.3%) and 5 patients (35.7%), respectively (p = 0.001). Six patients (42.9%) with CCPD stopped their first biotherapy course because of side effects. Among the patients with gout, urate-lowering therapy was more frequently used after (100%) than before the first biotherapy course (67.7%) (p = 0.002). CONCLUSION: Anakinra was prescribed for cases of refractory crystal-associated arthritis or cases with contraindications for usual treatments. The efficacy of anakinra in treating CCPD was not obvious. Patients with CCPD had more side effects. The biotherapy was introduced with a long-term objective, while anti-IL-1 therapies are approved for acute crises only.
Authors: Valerie Devauchelle-Pensec; Jean M Berthelot; Sandrine Jousse; Isabelle Samjee; Thierry Josseaume; Danielle Colin; Gerard Chalés; Jean B Thorel; Sylvie Hoang; Antoine Martin; Pierre Youinou; Paul Le Goff; Alain Saraux Journal: J Rheumatol Date: 2006-08 Impact factor: 4.666
Authors: Robert T Keenan; William R O'Brien; Kristen H Lee; Daria B Crittenden; Mark C Fisher; David S Goldfarb; Svetlana Krasnokutsky; Cheongeun Oh; Michael H Pillinger Journal: Am J Med Date: 2011-02 Impact factor: 4.965
Authors: Daniel H Solomon; Robert J Glynn; Jean G MacFadyen; Peter Libby; Tom Thuren; Brendan M Everett; Paul M Ridker Journal: Ann Intern Med Date: 2018-09-18 Impact factor: 25.391
Authors: Naomi Schlesinger; Marc De Meulemeester; Andrey Pikhlak; A Eftal Yücel; Dominik Richard; Valda Murphy; Udayasankar Arulmani; Peter Sallstig; Alexander So Journal: Arthritis Res Ther Date: 2011-03-25 Impact factor: 5.156
Authors: Eduardo Araújo Santana Nunes; Adroaldo Guimarães Rosseti; Daniel Sá Ribeiro; Mittermayer Santiago Journal: Case Rep Rheumatol Date: 2014-12-09
Authors: P Richette; M Doherty; E Pascual; V Barskova; F Becce; J Castañeda-Sanabria; M Coyfish; S Guillo; T L Jansen; H Janssens; F Lioté; C Mallen; G Nuki; F Perez-Ruiz; J Pimentao; L Punzi; T Pywell; A So; A K Tausche; T Uhlig; J Zavada; W Zhang; F Tubach; T Bardin Journal: Ann Rheum Dis Date: 2016-07-25 Impact factor: 19.103